

MAXIM.078A



RECEIVED

APR 30 2002

*Eff of issue
J. Mullen III
4/9/02*

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : K. Hellstrand, et al.

) Group Art Unit 1644


Appl. No. : 09/616,622

) I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first-class mail in
an envelope addressed to: United States Patent
and Trademark Office, P.O. Box 2327,
Arlington, VA 22202, on

Filed : July 14, 2000

April 22, 2002

(Date)


James J. Mullen III, Ph.D., Reg. No. 44,957

For : ACTIVATION AND
PROTECTION OF
CYTOTOXIC
LYMPHOCYTES USING A
REACTIVE OXYGEN
METABOLITE INHIBITOR

Examiner : G.R. Ewoldt

COPY OF PAPERS
ORIGINALLY FILED

AMENDMENT AND RESPONSE

United States Patent and Trademark Office
P.O. Box 2327, Arlington, VA 22202

Dear Sir:

This is in response to the Office Action mailed November 20, 2001 (Paper No. 8) for the above-referenced patent application. Reconsideration of the application in view of the amendments and remarks below is respectfully requested.

IN THE SPECIFICATION

Please amend the sentence on page 7, beginning at line 9 and ending at line 12 as follows:

In one embodiment the invention relates to a method comprising identifying a patient in need of enhanced cytotoxic lymphocyte activity, and administering to the patient an amount of diphenylene iodonium (DPI) effective to activate and protect cytotoxic lymphocyte function in the presence of MO.

04/26/2002 HNO0R1 00000041 09616622

01 FC:116

400.00 DP